■ Glaukos Corporation received FDA 510(k) clearance for its iPrime viscodelivery system, a sterile, single-use, minimally invasive device for the delivery of viscoelastic fluid during ophthalmic surgery.

“Since the introduction of our first iStent trabecular microbypass stent in 2012, Glaukos has pioneered the MIGS marketplace and led a transformation in the way ophthalmic surgeons manage chronic eye diseases,” said Glaukos President and CEO Thomas Burns in a news release. “We ... believe iPrime will be another important tool that supports the needs of physicians and patients.”